Application for ginseng-rhizoma curculiginis combined medicine for preparation for medicine used for treating osteoporosis
A technology for osteoporosis and drugs, applied in the direction of drug combinations, bone diseases, pharmaceutical formulations, etc., can solve the problems of no reports and achieve good curative effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0019] The preparation of embodiment 1 ginseng combination medicine
[0020] Weigh 25kg of Epimedium, 20kg of Ligustrum lucidum, 20kg of curculigo, 1kg of ginseng, and 15kg of Shouwu.
[0021] Mince Epimedium, extract with water, concentrate to a specific gravity of 1.2 g / cm3, soak in ethanol, and recover ethanol to obtain Epimedium extract;
[0022] Use ethanol to extract curculigo and Shouwu, recycle ethanol until the extract is 2-20 times the volume of the original medicinal material, stop recycling, add milk of lime to change the pH of the extract to 7-8, filter, and inject carbon dioxide gas into the filtrate to no Precipitation, aging treatment for 24 hours, and then filter, add acetic acid after the filter to adjust the pH value to 6-3, recover ethanol to obtain the curculigo-curculigo multiflorum extract;
[0023] Crush Ligustrum lucidum into Ligustrum lucidum powder, or extract Ligustrum lucidum extract with ethanol;
Embodiment 2
[0028] Example 2 Investigation of the Activity of Shenxian Combination Drugs on Senile Osteoporosis
[0029] Preventive effect on rat osteoporosis model induced by retinoic acid: 60 female rats weighing 170-200 g were randomly divided into 6 groups, namely normal control group (group A), model control group (group B), positive Control (Caltrate D 500 mg / kg) group (group C) and Shenxian combination drug groups I, II, and III described in Example 1 (dosage: 4.6 g of raw medicinal materials / kg), 10 rats in each group. Except for group A, the rest of the groups were given 70 mg / kg retinoic acid by intragastric administration every morning, and the corresponding dose of the test drug (administration volume 1ml / 100g body weight) by intragastric administration in the afternoon, 1 time / d, continuously. After 14 days of taking the medicine, retinoic acid was stopped, and the test drug was continued until 28 days. The next day after drug withdrawal, blood was collected from the jugular...
Embodiment 3
[0039] Example 3 Investigation of the Activity of Shenxian Combination Drugs on Osteoporosis Caused by Menopause
[0040] 56 unmated female SD rats for 3 months were raised in a clean environment with a room temperature of 25°C and a relative humidity of 80%, with free access to food and water; standard feed was used. Randomly divided into: sham operation group (group A); ovariectomized group. The ovariectomized group was further divided into: control group (group B); Caltrate-D group (group C); diethylstilbestrol group (group D), Shenxian combined drug group I (group E), Shenxian combined drug II Group (F group) and Shenxian combination drug group III (G group), 8 rats in each group. The rats were anesthetized with ether, operated aseptically, and entered the dorsal side of the rat abdominal cavity through a lumbar paravertebral incision, and the ovariectomized rats were removed. One week after the operation, the treatment group began to take a single dose by oral gavage. G...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More